
DarioHealth (DRIO) Stock Forecast & Price Target
DarioHealth (DRIO) Analyst Ratings
Bulls say
DarioHealth is a digital therapeutics company offering personalized interventions and behavior change through its health intelligence platform. It owns the entire value chain in chronic care management, resulting in longer engagement, stronger clinical outcomes, and optimal ROI. Despite missing revenue estimates for 2Q, the company's gross margin of 65% and partnerships with top health plans and Fortune 50 clients suggest potential for revenue growth and financial stability. Dario's acquisition of Twill in 2024 and introduction of its proprietary AI agent, DarioIQ, further demonstrate the company's commitment to innovation and expanding its product offerings. Potential risks in the HCIT space may impact the company, but its focus on B2B2C solutions and goal to reach cash flow breakeven by mid-2027 indicate a strong overall outlook. Additionally, Dario's thorough and comprehensive data analysis process allows for a clear understanding of its performance and potential areas for growth.
Bears say
DarioHealth is a digital therapeutics company with a vertically integrated health intelligence platform, delivering personalized interventions and focusing on longer engagement and stronger clinical outcomes. However, their Q2 results showed softer revenues and higher losses due to weaker demand in both the B2C and B2B channels. With limited visibility on the timing of contract signings and revenue acceleration, and potential risks of not reaching cash flow breakeven by mid-2027, it may be challenging for the company to achieve significant revenue growth and profitability in the near to medium term.
This aggregate rating is based on analysts' research of DarioHealth and is not a guaranteed prediction by Public.com or investment advice.
DarioHealth (DRIO) Analyst Forecast & Price Prediction
Start investing in DarioHealth (DRIO)
Order type
Buy in
Order amount
Est. shares
0 shares